Breaking Down SG&A Expenses: Biogen Inc. vs Veracyte, Inc.

A Comparative Analysis of SG&A Expenses: Biogen Inc. vs Veracyte, Inc.

In the ever-evolving landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Biogen Inc. and Veracyte, Inc. from 2014 to 2023. Biogen, a giant in the biotech sector, consistently allocated a significant portion of its budget to SG&A, with expenses peaking in 2021 at approximately 2.67 billion USD. This represents a 38% increase from 2014. In contrast, Veracyte, a smaller but rapidly growing company, saw its SG&A expenses rise by over 350% during the same period, reaching around 184 million USD in 2023. This stark contrast highlights the differing scales and growth trajectories of these companies. As Biogen focuses on maintaining its market dominance, Veracyte's increasing investment in SG&A underscores its aggressive expansion strategy.